These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 29679355)

  • 1. Valproate induced carnitine deficiency and hyperammonaemia.
    McCarron EP
    Clin Med (Lond); 2023 Jul; 23(4):429. PubMed ID: 37524421
    [No Abstract]   [Full Text] [Related]  

  • 2. Valproic acid as an adjuvant analgesic: adult Fanconi syndrome.
    Maybach A; Baro S; Kachurka K; Davis MP
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e942-e944. PubMed ID: 35764376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproate: Weighing the Unique Risks.
    Johnson EL
    Neurology; 2024 May; 102(9):e209325. PubMed ID: 38569129
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium Valproate-Induced Hyperpigmentation.
    Elwadhi A; Neha KC; Gupta D; Sharawat IK; Panda PK
    J Pediatr; 2023 Dec; 263():113660. PubMed ID: 37541425
    [No Abstract]   [Full Text] [Related]  

  • 5. Acetyl-l-carnitine deficiency in patients with major depressive disorder.
    Nasca C; Bigio B; Lee FS; Young SP; Kautz MM; Albright A; Beasley J; Millington DS; Mathé AA; Kocsis JH; Murrough JW; McEwen BS; Rasgon N
    Proc Natl Acad Sci U S A; 2018 Aug; 115(34):8627-8632. PubMed ID: 30061399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.
    Parvanova A; Trillini M; Podestà MA; Iliev IP; Aparicio C; Perna A; Peraro F; Rubis N; Gaspari F; Cannata A; Ferrari S; Bossi AC; Trevisan R; Parameswaran S; Chávez-Iñiguez JS; Masnic F; Seck SM; Jiamjariyaporn T; Cortinovis M; Perico L; Sharma K; Remuzzi G; Ruggenenti P; Warnock DG
    J Endocr Soc; 2018 May; 2(5):420-436. PubMed ID: 29696241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of valproate and naringin on kidney antioxidative markers and serum parameters of kidney function in C57BL6 mice.
    Jutrić D; Đikić D; Boroš A; Odeh D; Gračan R; Beletić A; Jurčević IL
    Arh Hig Rada Toksikol; 2023 Sep; 74(3):218-223. PubMed ID: 37791674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney tubular injury induced by valproic acid: systematic literature review.
    Anguissola G; Leu D; Simonetti GD; Simonetti BG; Lava SAG; Milani GP; Bianchetti MG; Scoglio M
    Pediatr Nephrol; 2023 Jun; 38(6):1725-1731. PubMed ID: 36645492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic-induced Fanconi syndrome: Clinical features, risk factors, diagnosis and management.
    Wang C; Zhou Y; Song L; Deng Z; Fang W
    Front Med (Lausanne); 2022; 9():945244. PubMed ID: 36186816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of sodium valproate on the renal function of children with epilepsy.
    Knights MJ; Finlay E
    Pediatr Nephrol; 2014 Jul; 29(7):1131-8. PubMed ID: 23720013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium valproate-induced Fanconi syndrome in two severely disabled patients receiving carnitine supplementation.
    Ono H
    Clin Exp Nephrol; 2019 Jan; 23(1):148-149. PubMed ID: 29679355
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium valproate -- induced skeletal myopathy.
    Kasturi L; Sawant SP
    Indian J Pediatr; 2005 Mar; 72(3):243-4. PubMed ID: 15812121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A severe disabled case of incomplete Fanconi syndrome after discontinuation of carnitine supplementation during valproate sodium therapy].
    Ono H
    No To Hattatsu; 2007 May; 39(3):226-7. PubMed ID: 17515139
    [No Abstract]   [Full Text] [Related]  

  • 15. Valproate-induced proximal renal tubular dysfunction: clinically relevant in the severely disabled epileptic population.
    Jaffe SL; Sanford M
    Epilepsia; 2005 Apr; 46(4):599-600. PubMed ID: 15816962
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.